trending Market Intelligence /marketintelligence/en/news-insights/trending/8V_h-Sc_wtmf7ashtjRIYw2 content esgSubNav
In This List

Report: Pfizer mulls sale of cardiology, urology, primary care drug portfolio

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Report: Pfizer mulls sale of cardiology, urology, primary care drug portfolio

Pfizer Inc. is weighing options for shedding a group of cardiology, urology and primary care drugs that generate more than $700 million in sales, Bloomberg News reported Feb. 2, citing "people familiar with the matter."

The New York-based drugmaker is reportedly considering selling the treatments as a package. The drugs generate about 40% of their sales from the U.S. and 45% of sales from Europe.

A potential sale could fetch the pharma giant more than $2 billion, according to the unnamed sources, who added that pharmaceuticals and private equity firms might be interested in the portfolio.

The company is working with JPMorgan Chase & Co. as financial advisers for the process, which is still in early stages, Bloomberg News reported.